Fierce Pharma

Amgen's Uplizna breaks into crowded myasthenia gravis market with FDA nod

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
The American Journal of Managed Care

There Is Great Need to Better Understand Pediatric Myasthenia Gravis: Jonathan Strober, MD

Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.
Zacks.com on MSN

JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price

Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...